Company profile

Executive Summary 

ABEOMICS, a San Diego, California based biotech company was founded in the year 2013 by Dr. Gita Singh to provide CRO service to biotech, pharma companies and the scientists in the research institues and universities. Subsequently, Abeomics has started developing and commercializing reagents for the scientific study of human biology and diseases and to produce new diagnostic assays and potential therapies for such diseases such as cancer, apoptosis (programmed cell death), molecular signaling pathways, cellular aging, metabolic disorder, neuro-degenerative, genetic and infectious diseases. 

The team at Abeomics comprises experienced scientists, including immunologists and cell biologists, who have contributed to the growth of global companies like BD Biosciences, eBioscience, and IMGENEX Corporation. This expertise enables Abeomics to develop well-validated and specific antibodies using traditional hybridoma technology and genetic engineering to produce recombinant mouse and rabbit monoclonal antibodies.

Mission

With a global presence through our distributors and a commitment to excellence, we specialize in custom cell line development, drug screening using our proprietay cell-based reporter assays. Our mission is to empower scientific through cutting-edge technologies. 

Drug discovery and development requires in-depth knowledge in targeted areas of biology, and experience in utilization of specific experimental platforms. Abeomics provides superb services for early stages of new drug development process including hit identification (compound screening)/ high throughput screening, hit to lead development, and lead optimization.

Company Summary 

Gita Singh, Ph.D.: Founder, President and CEO

More than 30 years of experience in biomedical research in academia and industries. Previous positions include Senior Scientists at PharMingen (now BD Biosciences), Vical, Inc and Vice President of R&D at IMGENEX Corporation, San Diego, CA. Expertise include cloning, recombinant protein expression in bacteria, baculovirus and mammalian cells and coordination of drug screening services.

Education: Ph.D. from University of Manchester, UK. 

Sujay Singh, Ph.D.: Vice President – Research and Development

More than 35 years of experience in biomedical research in academia and industries including Mayo Clinic, Vanderbilt University/Howard Hughes Medical Institute, Genentech, the UT Southwestern Medical Center, and PharMingen (now BD Biosciences). Dr. Singh was Founder and CEO of IMGENEX Corporation, San Diego, CA from 1997 till 2013. IMGENEX Corporation was acquired by Novus Biologicals in 2013. 

Education: Ph.D. in Genetics from Tuebingen University and Max-Planck Institute, Tuebingen, Germany.

Hyun-Ku Lee, Ph.D. Director, Bioassay Development & Screening. Dr. Lee has more than 25 years of experience in biomedical research. Previous positions include The Scripps Research Institutes, La Jolla, CA, IriSys, Inc. San Diego, and IMGENEX Corporation, San Diego. He has many years of experiences in the development of stable cell lines for protein production and stable reporter cell lines for drug screening using luciferase assay system.

Education: Ph.D. in Entomology & Neuroscience, University of California, Riverside, CA

Technology

1. Cell line Development:

1. Abeomics uses a proprietary mammalian expression vector for development of high-yield CHO cell lines for production of recombinant antibodies and protein. Abeomics also provides high-yield custom CHO cell line development for recombinant protein and antibody manufacturing for use in therapeutics. 

2. Cell-based reporter assays: Abeomics have developed many stable cell lines using luciferase-based assay system to study downstream signaling of NF-kB, NFAT, STAT, etc, which are ised for early-stage compound screening for new drug development. The greatest advantage of employing stable cell lines in cell-based assays and cell derived productions is to overcome the inconsistency in reproducibility of the expression level of gene of interest. It provides a long-standing, definite and reproducible expression of gene of interest.

2. Antibody Development and Characterization

1. Abeomics provides a full range of services for development of monoclonal antibodies and determination of antibody specificities. This includes western blot analysis, ELISA and flow cytometry. 

Recombinant antibody conversion. Includes sequencing of antibodies from hybridoma clones, conversion into recombinant antibodies, Ig class isotype switching and production of recombinant antibodies either in transient or stable expression system.

Products

1. Stable cell lines: Abeomics’ proprietary Reporter Cell Lines provide the most advanced system available for screening key pathways involved in immune regulation and inflammation. 

The innovative Leeporter™ Stable Reporter Cell Lines feature target promoters or upstream response elements for numerous critical pathways such as TLRs/RLRs, Interleukins, p53 pathway, Nrf2, Wnt pathway, STAT and NF-κB pathways, all driving Renilla Luciferase reporter gene expression. These Luciferase Reporter Cell Lines have undergone extensive functional characterization, demonstrating broad working range dynamics and high sensitivity, making them ideal for high-throughput screening of small molecules. Leeporter™ Luciferase Reporter 

2. Cell Lines and assay systems are integral to Abeomics Drug Discovery Screening Services and Compound Screening Services and are also available for direct purchase. Abeomics continually expands its offerings with new modulators, compound libraries, and Reporter Cell Lines to explore mechanisms of action and develop potential treatments for various diseases.

3. Antibodies: The antibody has an extensive portfolio of monoclonal and polyclonal antibodies to study apoptosis, cell signaling, development and differentiation, DNA methylation and repair, infectious diseases, etc.

4. Biosimilar antibodies: Biosimilars are biological products such as proteins and antibodies that are highly analogous to FDA approved biologic reference products and have no clinically meaningful differences in terms of safety and effectiveness from reference products. Biosimilar monoclonal antibodies are an important part of the biosimilar family that can be used in the treatment of diseases like cancer and autoimmune disorders and is also important for research use.

Abeomics provides an array of biosimilar recombinant monoclonal antibodies that include Recombinant anti-human ErbB2/HER2 Antibody (Trastuzumab), Anti-Human CD11a (Efalizumab), Anti-Human CD194 (CCR4) (Mogamulizumab) and many more.